Neurotransmitter interactions in schizophrenia—therapeutic implications
- 1 November 1999
- journal article
- review article
- Published by Elsevier in Biological Psychiatry
- Vol. 46 (10), 1388-1395
- https://doi.org/10.1016/s0006-3223(99)00117-1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in miceJournal of Neural Transmission, 1999
- Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography methodProceedings of the National Academy of Sciences, 1997
- Presynaptic dopaminergic function in the striatum of schizophrenic patientsSchizophrenia Research, 1997
- The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosisJournal of Neural Transmission, 1995
- Low brain uptake of L‐[11C]5‐hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteersActa Psychiatrica Scandinavica, 1991
- Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's diseaseTrends in Neurosciences, 1990
- Functional architecture of basal ganglia circuits: neural substrates of parallel processingTrends in Neurosciences, 1990
- Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systemsPharmacology Biochemistry and Behavior, 1990
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal of Neural Transmission, 1989
- The current status of the dopamine hypothesis of schizophreniaNeuropsychopharmacology, 1988